Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience.
Cerebral venous thrombosis
DOAC
Factor Xa inhibitor
Rivaroxaban
Journal
Acta neurologica Belgica
ISSN: 2240-2993
Titre abrégé: Acta Neurol Belg
Pays: Italy
ID NLM: 0247035
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
31
12
2020
accepted:
08
03
2021
pubmed:
19
3
2021
medline:
22
3
2022
entrez:
18
3
2021
Statut:
ppublish
Résumé
The mainstay of cerebral venous thrombosis (CVT) treatment according to current guidelines is parenteral anticoagulation with unfractionated heparin or low-molecular-weight heparin followed by long-term oral anticoagulation with vitamin K antagonists. Direct oral anticoagulants (DOACs), including the factor Xa inhibitor rivaroxaban, are used occasionally off-label for CVT based on individual treatment plans. This publication sought to report our experience with rivaroxaban for the indication of CVT and to review the relevant literature data concerning this topic. We performed a single-center retrospective analysis including patients from our institution with the diagnosis of cerebral venous thrombosis treated with rivaroxaban. Among 12,500 stroke patients over an 11-year period, we identified 87 cases with a diagnosis of CVT (0.7%). As long-term anticoagulation, 80 of these patients were receiving vitamin K antagonists and seven were receiving DOACs, including six receiving rivaroxaban and one receiving apixaban. Of the six patients receiving rivaroxaban, at least 6 months of clinical follow-up data were available for five of them. Excellent clinical outcomes were obtained in four of these five cases (modified Rankin scale score: 0-1 points). No hemorrhagic events, recurrent thrombosis, or other relevant complications were recorded during the follow-up period. Despite our small study sample size, our positive results support that rivaroxaban may be a safe and effective treatment option for patients with CVT. Hopefully, ongoing randomized clinical trials will better clarify the role of rivaroxaban in the treatment of CVT so as to provide a more convenient and safer alternative to vitamin K antagonists in this context.
Identifiants
pubmed: 33733345
doi: 10.1007/s13760-021-01651-z
pii: 10.1007/s13760-021-01651-z
doi:
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-111Informations de copyright
© 2021. Belgian Neurological Society.
Références
Bushnell C, Saposnik G (2014) Evaluation and management of cerebral venous thrombosis. Continuum (Minneap Minn). 20(2):335–351
pubmed: 24699485
Bousser MG, Ferro JM (2007) Cerebral venous thrombosis: an update. Lancet Neurol 6(2):162–170
doi: 10.1016/S1474-4422(07)70029-7
Bando T, Ueno Y, Shimo D, Kuroyama T, Mikami K, Hori S, Hirai O (2020) Clinical trial based rationale for the successful use of DOAC in the treatment of cerebral venous sinus thrombosis (CVST): a case report. J Stroke Cerebrovasc Dis 29(11):105261
doi: 10.1016/j.jstrokecerebrovasdis.2020.105261
Ehtisham A, Stern BJ (2006) Cerebral venous thrombosis: a review. Neurologist 12(1):32–38
doi: 10.1097/01.nrl.0000178755.90391.b6
Feher G, Illes Z, Hargroves D, Komoly S (2016) Do we have to anticoagulate patients with cerebral venous thrombosis? Int Angiol 35(4):369–373 (Epub 2015 May 28)
pubmed: 26017760
Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, di Minno M, Maino A, Martinelli I, Masuhr F, Aguiar de Sousa D, Stam J (2017) European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. European Stroke Organization. Eur J Neurol 24(10):1203–1213
doi: 10.1111/ene.13381
Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Bousser MG, Stam J, ISCVT Investigators (2010) Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 41(11):2575–2580
doi: 10.1161/STROKEAHA.110.588822
Misra UK, Kalita J, Chandra S, Kumar B, Bansal V (2012) Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol 19(7):1030–1036
doi: 10.1111/j.1468-1331.2012.03690.x
Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, Veber G, Ferro JM, Tsai FY (2011) Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Stroke 42(4):1158–1192
doi: 10.1161/STR.0b013e31820a8364
Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, Karpov D, Nagel S, Posthuma L, Roriz JM, Caria J, Frässdorf M, Huisman H, Reilly P, Diener HC, RE-SPECT CVT Study Group (2019) Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 76(12):1457–1465
doi: 10.1001/jamaneurol.2019.2764
Geisbüsch C, Richter D, Herweh C, Ringleb PA, Nagel S (2014) Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke 45(8):2469–2471
doi: 10.1161/STROKEAHA.114.006167
Feher G, Illes Z, Komoly S, Hargroves D (2016) Novel oral anticoagulants in the treatment of cerebral venous thrombosis. Int Angiol 35(4):365–368
pubmed: 25994451
Dmytriw AA, Song JSA, Yu E, Poon CS (2018) Cerebral venous thrombosis: state of the art diagnosis and management. Neuroradiology 60(7):669–685
doi: 10.1007/s00234-018-2032-2
Mekaj YH, Mekaj AY, Duci SB, Miftari EI (2015) New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 11:967–977
doi: 10.2147/TCRM.S84210
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365(10):883–891
doi: 10.1056/NEJMoa1009638
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510
doi: 10.1056/NEJMoa1007903
Imberti D, Pomero F, Mastroiacovo D (2020) Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Blood Transfus 18(1):49–57
pubmed: 31184579
pmcid: 7053524
Bose G, Graveline Y, Yogendrakumar V, Fergusson D, Dowlatshahi D (2019) Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol. Syst Rev 8:99. https://doi.org/10.1186/s13643-019-1022-8 (Published online 2019 Apr 18)
doi: 10.1186/s13643-019-1022-8
pubmed: 30999965
pmcid: 6474061
Mutgi SA, Grose NA, Behrouz R (2015) Rivaroxaban for the treatment of cerebral venous thrombosis. Int J Stroke 10(Suppl A100):167–168
doi: 10.1111/ijs.12592
Anticoli S, Pezzella FR, Scifoni G, Ferrari C, Pozzessere C (2016) Treatment of cerebral venous thrombosis with rivaroxaban. J Biomed Sci 5:3
Kusuma IA (2017) The use of new oral anticoagulant in cerebral venous sinus thrombosis: alternative therapy with excellent result. J Clin Exp Cardiol 8:5 (Suppl)
Sui J, Zhang Y, Yang L, Wang H, Xu J, Wei R, Hao Y, Wang X, Peng J, Ma J (2017) Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: a case report and literature review. Med (Baltimore) 96(46):e8715
doi: 10.1097/MD.0000000000008715
Bajkó Z, Andone S, Buruian M, Filep R, Balasa R (2020) Unilateral deep cerebral venous sinus thrombosis with reversible secondary parkinsonism. Acta Neurol Belg 120(2):503–506. https://doi.org/10.1007/s13760-018-0982-0 (Epub 2018 Jul 9)
doi: 10.1007/s13760-018-0982-0
pubmed: 29987553
Shankar Iyer R, Tcr R, Akhtar S, Muthukalathi K, Kumar P, Muthukumar K (2018) Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients. Clin Neurol Neurosurg 175:108–111
doi: 10.1016/j.clineuro.2018.10.015
Covut F, Kewan T, Perez O, Flores M, Haddad A, Daw H (2019) Apixaban and rivaroxaban in patients with cerebral venous thrombosis. Thromb Res 173:77–78
doi: 10.1016/j.thromres.2018.11.018
Rusin G, Wypasek E, Papuga-Szela E, Żuk J, Undas A (2019) Direct oral anticoagulants in the treatment of cerebral venous sinus thrombosis: a single institution’s experience. Neurol Neurochir Pol 53(5):384–387
pubmed: 31454061
Powell M, Tremolet de Villers K, Schwarz K, Case D, Trujillo T (2020) A single-center retrospective evaluation of the use of oral factor Xa inhibitors in patients with cerebral venous thrombosis. Ann Pharmacother. https://doi.org/10.1177/1060028020952749
doi: 10.1177/1060028020952749
pubmed: 32844675
Stolz E, Trittmacher S, Rahimi A, Gerriets T, Röttger C, Siekmann R, Kaps M (2004) Influence of recanalization on outcome in dural sinus thrombosis: a prospective study. Stroke 35(2):544–547
doi: 10.1161/01.STR.0000112972.09096.65